PGNYProgyny, Inc.
The financials
Progyny, Inc. by the numbers
Progyny, Inc. (PGNY) reported revenue of $341M in Q3 2026 (quarter ended Sep 30, 2026), up 8.9% from the same quarter a year earlier. That came with a gross margin of 25% and net income of $26M (7.7% of revenue). For the full year FY2025, revenue was $1.29B (+10% year on year) and net income $59M. Its largest product in Q3 2026 was Fertility benefit services at $223M, 65% of the disclosed total, well ahead of Pharmacy benefit services at 35%. The next results filing is expected around Feb 3, 2027, a quarter after the last one.
| Income statement | Q3 2026 | Q3 2025 | Change |
|---|---|---|---|
| Revenue | $341M | $313M | +8.9% |
| Gross profit | $84M | $73M | +15% |
| Operating income | $35M | $22M | +63% |
| Net income | $26M | $14M | +89% |
| Diluted EPS | $0.32 | $0.15 | +113% |
| Product | Revenue | Share |
|---|---|---|
| Fertility benefit services | $223M | 65% |
| Pharmacy benefit services | $118M | 35% |
Over its last three fiscal years Progyny, Inc. booked income tax of 29.9% of its pretax profit, 35.8% once deferred tax is taken out, above the 21.3% median for US companies in our tax study.
Business segments
Revenue split by product segment, from SEC XBRL filings.
- Fertility benefit services$223.4M$223.4Mvs last quarter -3.0%vs a year ago +11%-3.0%+11%
- Pharmacy benefit services$117.9M$117.9Mvs last quarter -2.0%vs a year ago +5.8%-2.0%+5.8%